BioLine RX Ltd（BLRX）股票分析

$1.730

-0.037 (-2.15%)收盘时

Loading chart…

最高: 1.750
开盘: 1.715
成交量加权均价: 1.73
成交量: 7.76K
市值: 45.57M
最低: 1.709
成交额: 13.42K
企业价值/息税折旧摊销前利润（TTM）: -0.45

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

www.biolinerx.com

AI 分析 of BioLine RX Ltd (BLRX)

卖出

BioLine RX Ltd is not a good buy right now due to its current price of $1.73, a very low RSI of 11.115 indicating oversold conditions, and a staggering 49.71% decline over the past year. The company also reported a widening net loss of $4.3 million in Q2 2026, which raises concerns about its financial health and sustainability.

分析师评级（4）

上行空间 +593.64%

买入

4 买入

0 持有

0 卖出

当前: 1.73

最低

12.00

平均

12.00

最高

12.00

Jones Trading

持有

—

2025-04-02

Jones Trading

2025-04-02

目标价

—

持有

HC Wainwright & Co.

强烈买入

$26

2025-03-31

HC Wainwright & Co.

2025-03-31

目标价

$26

强烈买入

HC Wainwright & Co.

强烈买入

2024-11-25

HC Wainwright & Co.

2024-11-25

目标价

强烈买入

HC Wainwright & Co.

强烈买入

$21

2024-11-06

HC Wainwright & Co.

2024-11-06

目标价

$21

强烈买入

Jones Trading

强烈买入

2024-09-04

Jones Trading

2024-09-04

目标价

强烈买入

查看全部评级

估值指标

BioLine RX Ltd（BLRX）当前预期市盈率为 93.46，5 年平均预期市盈率为 15.21。

预期市盈率

严重高估

5 年均值 P/E

15.21

当前P/E

93.46

高估

53.08

低估

-22.67

预期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-1.03

当前EV/EBITDA

-0.45

高估

0.32

低估

-2.39

预期市销率

合理

5 年均值 P/S

14.00

当前P/S

3.96

高估

56.66

低估

-28.65

Alphio AI 对 BLRX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。

乐

乐观

乐观 · 25%BLRX

$4.97

情景价格

基

基准

基准 · 50%BLRX

$4.62

情景价格

悲

悲观

悲观 · 25%BLRX

$4.26

情景价格

事件时间线

2026-09-25 (ET)